The Nomination Committee of Acarix consists of Jan Poulsen (Chairman) representing Life Science Invest Fund 1 among others, Anton Rehnström representing Anton Rehnström and Philip Siberg, Chairman of the Board of Acarix.

The Nomination Committee has carried out an intensive and comprehensive process including the evaluation of the existing competencies in relation to the strategic plan of Acarix with focus on the US market. The Committee has assessed that there was a need to strengthen the Board by adding new competencies with a more direct and comprehensive insight into the US market and cardiac space.

After having caried out an international search process and interviewed a significant number of candidates, the Nomination Committee is extremely pleased to note that, based on the company's unique technology and potential, it has been possible to attract some highly qualified US based board members.

The Nomination Committee proposes the re-election of Philip Siberg and Marlou Janssen-Counotte and the election of Mr. Ken Nelson and Dr. Tony Das as new members of the board. The Nomination Committee further proposes that Philip Siberg is re-elected as chairman of the board.

After 10 years on the board, Ulf Rosén announced that he was not available for re-election. Ulf Rosén will continue to support the company as a major shareholder. The Nomination Committee wishes to express its gratitude for the valuable contribution from Ulf Rosén over many years. The Nomination Committee also wants to thank Fredrik Buch and Mikael Thorén for their valuable contributions as board members of Acarix.

Presentation of Ken Nelson:
Ken Nelson is a 20 year digital health, medical device, and remote patient monitoring executive and innovator with successful senior leadership experience ranging from a Fortune 500 company (Guidant/ Boston Scientific in Cardiac Rhythm Management) to a #1 market share leading medium sized company (Biotelemetry, acquisition by Philips for $2.8 Billion announced in December '20) to 3 start-ups, 1 of which eventually led to an extremely successful IPO (iRhythm) and another which was just acquired by HillRom/ Baxter (Bardy Diagnostics) in August 2021 for $450M+ after milestone payments.

He currently serves as partner in the Medtech Advantage Fund, which has an exclusive partnership with Medtech Innovator (www.medtechinnovator.org ), the largest MedTech and Digital Health startup accelerator globally. In addition, he serves on the Boards of Directors of CardiaCare, HeartBeam (NASDAQ:  BEAT), and Happitech. He is also on the advisory boards and/or planning committees, for SmartCardia, Bloomlife, AccurKardia, HeartX (MedAxiom/ ACC), HRX (Digital Health Summit of Heart Rhythm Society), and the American Heart Association.

Presentation of Dr. Tony Das, MD, FACC:
Dr. Das is a board-certified interventional cardiologist. A national expert in Cardiovascular Interventions and Digital Health with 25 years of experience leading collaborative teams, developing programs and creating value in the cardiovascular healthcare space.

Dr. Das is the founder of Connected Cardiovascular Care Associates (C3) the first US cardiology practice dedicated to a Digital First approach for CV care using remote monitoring services. Dr. Das also serves as Chief of Digital Health, Cardiovascular Innovation and Business Development/Strategy for Baylor Scott and White Healthcare Heart Hospitals. Dr. Das is a committee member for national cardiology societies, including the ACC Wearable Device and Innovation committee and the AHA National Cardiac Innovation group.

Dr. Das has led strategy and development for over a dozen early-stage companies through the FDA approval and commercialization process in the CV space. Dr. Das is a medical venture partner in three healthcare venture capital groups, including Biostar Capital, Sheltowee Med-tech fund and the Korenvaes Family
Office having raised over $150M for healthcare startups.

While practicing in Dallas since 1996 Dr. Das has been honored as Best Cardiologist in Dallas by D. Magazine, Best Cardiologist in Texas by the Texas Monthly Magazine and Best Cardiologists in the US by Castle Conoly group. Dr. Das is also the personal interventional cardiologist to former President George W. Bush.

For any questions regarding the proposal, please contact the chairman Jan Poulsen at jp@lsif.dk or +45 5354 0000.

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

Attachments
Proposal by the nomination committee prior to the 2024 annual general meeting of Acarix AB (publ)

© Modular Finance, source Nordic Press Releases